We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response.
- Authors
Dae Hun Kwon; In Hee Kim; Bum Su Choung; Dae Seon Ahn; Sun Ho Yoo; Sang Bae Park; Seok Lee; Seong Hun Kim; Sang Wook Kim; Yong Jin Im
- Abstract
Background/Aims: We investigated the efficacy of continuous long-term entecavir 0.5 mg treatment in naïve chronic hepatitis B patients showing a partial virologic response (PVR). Methods: A total of 227 patients were included. PVR was defined as a more than 1 log10 IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR; ⩾20 IU/mL) at week 48. A complete virologic response (CVR) was defined as undetectable serum HBV DNA by PCR (<20 IU/mL) at week 48. Results: At week 48, the rate of the PVR was 64/227 (28.2%). Among patients with PVR, the cumulative rates of virologic response (serum HBV DNA <20 IU/mL) at weeks 96 and 144 were 45.2% and 73.8%, respectively. The cumulative rates of genotypic resistance were not significantly different between patients with a PVR and patients with a CVR (p=0.057). However, the cumulative rates of virologic breakthrough were higher in patients with PVR than in patients with CVR (4% vs 0% and 11.2% vs 0% at weeks 96 and 144, respectively; p<0.001). Conclusions: Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.
- Publication
Gut & Liver, 2013, Vol 7, Issue 6, p712
- ISSN
1976-2283
- Publication type
Academic Journal
- DOI
10.5009/gnl.2013.7.6.712